Responses
Ovarian cancer
2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine
Compose a Response to This Article
Other responses
No responses have been published for this article.